Eslam Habba
Tanda, GH, Egypt
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Correction to: Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: July 05, 2026
Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 21, 2026
Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 21, 2026
Immunomodulatory and Anti-Inflammatory Effects of Ketotifen Versus Vitamin E in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Pilot Study.
Journal: Drug design, development and therapy
Published: January 04, 2026
Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.
Journal: Frontiers in pharmacology
Published: August 22, 2025
Comparative efficacy of febuxostat and vitamin E in the management of MASLD: Insights from a randomized parallel clinical study.
Journal: European journal of pharmacology
Published: March 12, 2025
Aetiology of Fever of Unknown Origin in Two Middle Delta Egyptian Tertiary Health Care Facilities.
Journal: Recent advances in anti-infective drug discovery
Published: August 11, 2024
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.
Journal: European review for medical and pharmacological sciences
Published: September 05, 2023
Nitazoxanide-based therapeutic regimen as a novel treatment for Helicobacter pylori infection in children and adolescents: a randomized trial.
Journal: European review for medical and pharmacological sciences
Published: May 19, 2022
A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.
Journal: Medicine
Published: June 17, 2016
Showing 1-11 of 11
Last Updated: 09/26/2026